Long-Term irAEs From Checkpoint Inhibitors Have Considerations for Survivorship
Elisa Becze, BA, ELS, Editor
Voice
Description
More than 40% of patients with melanoma treated with nivolumab or pembrolizumab experience persistent long-term immune-related adverse events (irAEs) for at least 1.5 years, researchers reported in JAMA Oncology.